MYP_135990
Tildrakizumab
Anticancer
Immunology
▸
Immune modulation
▸
Immunomodulatory activity
Standard
446 amino acids
C2172H3365N573O666S17
Standard
QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
48705.50 Da
8.49
5.46
4.52
0.0123
-0.37
0.54
0.02
42.65
68.52
0.0942
77810.00
78435.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Amino Acid Composition
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
RECORD: Rec_0119245
VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Monoclonal antibody
32630
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Immunomodulatory
The half-life is approximately 23 days (23%) [L1858].
RECORD: Rec_0409161
VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Monoclonal antibody
32630
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Immunomodulatory
The half-life is approximately 23 days (23%) [L1858].